Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:

NCT ID: NCT04643405 Recruiting - Clinical trials for Advanced Pancreatic Cancer

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Start date: March 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.

NCT ID: NCT04617067 Completed - Clinical trials for Advanced Pancreatic Cancer

Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer

Start date: October 16, 2020
Phase: Phase 2
Study type: Interventional

The trial is designed to establish whether adding a vitamin D analogue, Paricalcitol, to standard chemotherapy treatment, Gemcitabine and Nab-paclitaxel, can improve the outcomes for patients with advanced pancreatic cancer.

NCT ID: NCT04482257 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer.

Start date: July 7, 2020
Phase: Phase 1
Study type: Interventional

Randomized, Open-label, Single-dose, Two-sequence, Two-period, Crossover Bioequivalence Trial of Irinotecan Liposome Injection in Patients With Advanced Pancreatic Cancer.

NCT ID: NCT04469556 Active, not recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Pancreatic Adenocarcinoma Signature Stratification for Treatment

PASS-01
Start date: October 14, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized multicentre phase II trial with a large translational component. The trial will evaluate the two standard chemotherapy regimens: modified folfirinox (mFFX) and gemcitabine/nab-paclitaxel (GA), in patients with untreated metastatic pancreatic ductal adenocarcinoma. Integrated into this phase II trial are a number of laboratory components including molecular profiling, patient derived organoid establishment, and drug testing sensitivity and other biomarkers.

NCT ID: NCT04239001 Recruiting - Clinical trials for Advanced Pancreatic Cancer

Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer

Start date: February 2020
Phase: N/A
Study type: Interventional

A prospective, open, one-arm clinical study to evaluate the efficacy and safety of jinyouli in the first-line treatment of advanced pancreatic cancer with albumin paclitaxel combined with S-1.Chemotherapy regimen: (1) chemotherapy: albumin paclitaxel, 120mg / m2, intravenous infusion for 30 minutes, D1. S-1, taken orally after meal, D1 - 14. (2) patients who met the input / discharge criteria were given jinyouli injections 24 hours after the end of intravenous infusion of albumin paclitaxel during the treatment period.

NCT ID: NCT04228601 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Start date: January 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to: a) evaluate the tolerability and safety of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer, and establish the maximum tolerated dose and recommended phase II dose of the combination; and b) assess the efficacy of the co-administration of Fluzoparib and mFOLFIRINOX followed by Fluzoparib Maintenance Monotherapy in patients with advanced pancreatic cancer.

NCT ID: NCT04217096 Not yet recruiting - Clinical trials for Advanced Pancreatic Cancer

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

The present study is intended to investigate the efficacy and safety of the patients with confirmed advanced pancreatic cancer after treating with the combination of paclitaxel liposome plus S-1.

NCT ID: NCT04137536 Active, not recruiting - Pancreatic Cancer Clinical Trials

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

Start date: October 17, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the safest dose and identify any bad side effects of EGFR-BATs (bispecific antibody-armed activated T cells) for people with advanced pancreatic cancer who have already received first-line standard chemotherapy.

NCT ID: NCT04104672 Recruiting - Clinical trials for Advanced Pancreatic Cancer

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

ARC-8
Start date: November 6, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.

NCT ID: NCT04098081 Recruiting - Clinical trials for Advanced Pancreatic Cancer

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

Start date: December 12, 2019
Phase: Phase 2
Study type: Interventional

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma